

The  
United  
States  
of  
America



The Commissioner of  
Patents and Trademarks

*Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this*

United States Patent

*Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.*

*If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.*

*If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.*

*J. Todd Johnson*

Acting Commissioner of Patents and Trademarks


*Margorie V. Turner*

Attest

# 2

JC406 U.S. PTO  
09/687144





US005928671A

**United States Patent** [19]**Domenico**[11] **Patent Number:** **5,928,671**[45] **Date of Patent:** **\*Jul. 27, 1999****[54] METHOD AND COMPOSITION FOR INHIBITING BACTERIA**[75] **Inventor:** **Philip Domenico, Elmhurst, N.Y.**[73] **Assignee:** **Winthrop University Hospital, Mineola, N.Y.**

[\*] **Notice:** This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

[21] **Appl. No.:** **08/883,584**[22] **Filed:** **Jun. 26, 1997****Related U.S. Application Data**

[63] Continuation of application No. 08/428,464, Apr. 25, 1995, abandoned.

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 31/095; A61K 33/24**[52] **U.S. Cl.** ..... **424/653; 514/706**[58] **Field of Search** ..... **424/653; 514/706****[56] References Cited****U.S. PATENT DOCUMENTS**

- 2,809,971 10/1957 Bernstein et al. .... 260/270
- 3,583,999 6/1971 Damico ..... 260/294.8
- 3,753,990 8/1973 Curry ..... 260/270
- 3,773,770 11/1973 Damico ..... 260/290
- 3,833,565 9/1974 Curry ..... 260/270
- 3,852,441 12/1974 Kooistra, Jr. .... 424/245
- 3,890,242 6/1975 Curry ..... 252/107
- 4,374,825 2/1983 Bolich, Jr. et al. .... 424/70
- 4,524,110 6/1985 Heeres et al. .... 428/537.1
- 4,963,344 10/1990 Gries et al. .... 424/9
- 5,104,645 4/1992 Cardin et al. .... 424/70
- 5,541,233 7/1996 Roenigk ..... 521/54
- 5,593,670 1/1997 Trinh et al. .... 424/76.1
- 5,596,102 1/1997 Austin ..... 548/101
- 5,605,681 2/1997 Trandai et al. .... 424/65
- 5,624,666 4/1997 Coffindaffer et al. .... 424/70.21
- 5,643,971 7/1997 Roenigk ..... 523/122

**FOREIGN PATENT DOCUMENTS**

- 9412034 6/1994 WIPO .

**OTHER PUBLICATIONS**

- W. Beil et al., *Pharmacology* 50:333-337 (1995).
- D.W. Bierer, *Rev. Infect. Dis.* 12(1):S3-S8 (1990).
- D. Chaleil et al., *J. Inorg. Biochem.* 15:213-221 (1981).
- N.A. Cornick et al., *Rev. Infect. Dis.* 12(1):S9-S10 (1990).
- J.S. Dixon, *Scand. J. Gastroenterol.* 30(212):48-62 (1995).
- P. Domenico et al., *J. Antimicro. Chemo.* 28:801-810 (1991).

- P. Domenico et al., *Infection* 20(2):18/66-23/71 (1992).
- P. Domenico et al., *Eur. J. Clin. Microbiol. Infec. Dis.* 11:170-175 (1992).
- P. Domenico, "Comparative Antibacterial Properties of Bismuth-Dimercaprol and Chlorhexidine," 95th Gen'l. Meeting Amer. Soc. Microbiol., Washington, D.C. (May 1995).
- P. Domenico et al., "Bismuth-Dimercaprol Activity Against Multiply Resistant Gram-Positive Bacteria," *Clin. Res. Meeting, Abstract* (May 1995).
- P. Domenico et al., *In vitro Antifungal Activities of BisBAL and BisME, Two Thiol-Chelated Bismuth Compounds*, 36th ICAAC, Abstract F188 (Sep. 1996).
- P. Domenico et al., "Efficacy/Toxicity of Bismuth-Dimercaprol in a Burn Wound Sepsis Model," 96th ASM General Meeting, Abstract A10 (May 1996).
- P. Domenico et al., "Antimicrobial Activity of the Bismuth-Thiol Chelates, BisBAL and BisME," *Clin. Res.* 44:332A, Abstract (1996).
- P. Domenico et al., *Annals of N.Y. Acad. Sci.* 797:269-270 (1996).
- P. Domenico et al., *Antimicrob. Agents and Chemo.* 38(6):1031-1040 (1997).
- P. Domenico et al., *Antimicrob. Agents and Chemo.* 41(8):1697-1703 (1997).
- P. Domenico et al., "Potentiation of Bismuth Antibacterial Activity by Thiol Chelators," 97th ASM Gen'l. Meeting, Florida, Official Abstract Form & Abstract A-43 (May 1997).
- B.E. Douglas et al., *Concepts and Models of Inorganic Chem.*, 3rd Ed. pp. 463-465 (1994).
- H.L. DuPont et al., *New Eng. J. Med.* 328:1821-1827 (1993).
- D. Figueroa-Quintanilla et al., *New Eng. J. Med.* 328(23):1653-1658 (1993).
- S.L. Gorbach et al., *Reviews of Infec. Dis.* 12(1):S21-S23 (1990).
- Gould et al., "Activity of the Novel Compounds BisBAL and BisME Against *Burkholderia cepacia*," 36th ICAAC, Louisiana, Abstract F246 (1996).

(List continued on next page.)

**Primary Examiner**—Phyllis Spivack**Attorney, Agent, or Firm**—Ostrolenk, Faber, Gerb & Soffen, LLP

[57]

**ABSTRACT**

A composition comprising a trivalent bismuth salt, particularly bismuth nitrate, and dimercaprol is described. Methods for using the composition as a bacteriocidal and bacteriostatic agent and as a disinfectant and preservative are also provided.

**18 Claims, 1 Drawing Sheet**